Results 11 to 20 of about 1,261,156 (366)

Comparison of the adverse event profiles of conventional and liposomal formulations of doxorubicin using the FDA adverse event reporting system. [PDF]

PLoS ONE, 2017
Doxorubicin (DOX) is an anthracycline widely used for the treatment of solid and hematological tumors. The aim of this study was to assess the adverse event profiles of conventional DOX and liposomal DOX. This is the first study to evaluate the effect of
Akiho Fukuda, Kohei Tahara, Yuuki Hane, Toshinobu Matsui, Sayaka Sasaoka, Haruna Hatahira, Yumi Motooka, Shiori Hasegawa, Misa Naganuma, Junko Abe, Satoshi Nakao, Hirofumi Takeuchi, Mitsuhiro Nakamura   +12 more
doaj   +3 more sources

Indications and adverse events of teriparatide: based on FDA adverse event reporting system (FAERS)

Frontiers in Pharmacology
BackgroundTeriparatide is approved for osteoporosis. Post-marketing surveillance is critical given its widespread use.ObjectiveTo investigate adverse events (AEs) associated with teriparatide using the FAERS database, compare association strengths for ...
Ming-Tao Wen, Jia-Cheng Li, Jia-Cheng Li, Bo-Wen Lu, Hua-Rong Shao, Pei-Xue Ling, Fei Liu, Fei Liu, Gang Li, Gang Li, Di Luo, Di Luo   +11 more
doaj   +3 more sources

Serious Adverse Drug Events Reported to the FDA: Analysis of the FDA Adverse Event Reporting System 2006-2014 Database [PDF]

Journal of Managed Care & Specialty Pharmacy, 2018
Data on adverse drug events (ADEs) observed at the population level provide important evidence regarding the safety of a pharmaceutical product in real-world settings. Recent patterns in serious and fatal ADE reporting have not been documented.To assess recent patterns in serious and fatal ADE reports in the United States.We conducted a retrospective ...
Kalyani Sonawane, Ning Cheng, Richard A. Hansen   +2 more
openalex   +4 more sources

Evaluation of atypical antipsychotics associated rhabdomyolysis using the FDA adverse event reporting system database [PDF]

Scientific Reports
Rhabdomyolysis is a potentially fatal adverse reaction mainly caused by certain medications. Few real-world studies have shown a clear association between atypical antipsychotics and rhabdomyolysis.
Yi Yin, Jie Jiang, Youpeng Jin
doaj   +2 more sources

Oseltamivir-induced hepatotoxicity: A retrospective analysis of the FDA adverse event reporting system. [PDF]

PLoS ONE
Assessing the potential for oseltamivir-induced liver damage is essential to ensure its safe administration. The aim of this study was to examine the association between hepatotoxicity and oseltamivir use and to describe the features of oseltamivir ...
Lurong Yu, Qiumeng Xiang, Limei Liu
doaj   +2 more sources

Adverse event profiles of dipeptidyl peptidase-4 inhibitors: data mining of the public version of the FDA adverse event reporting system [PDF]

BMC Pharmacology and Toxicology, 2020
Background To describe and analyze the patterns of adverse events associated with dipeptidyl peptidase-4 inhibitors (DPP-4is) (sitagliptin, saxagliptin, linagliptin, vildagliptin, and alogliptin) from the FDA Adverse Event Reporting System (FAERS) and to
Jing Huang, Yuntao Jia, Shusen Sun, Long Meng   +3 more
doaj   +2 more sources

Human papillomavirus vaccine-associated premature ovarian insufficiency and related adverse events: data mining of Vaccine Adverse Event Reporting System [PDF]

Scientific Reports, 2020
We detected disproportionate reports of premature ovarian insufficiency (POI) and related events, including amenorrhea, menstruation irregular, FSH increased, and premature menopause, following human papillomavirus (HPV) vaccine from FDA Vaccine Adverse ...
Li Gong, Huanhuan Ji, Xuewen Tang, Lingyun Pan, Xiao Chen, Yuntao Jia   +5 more
openalex   +2 more sources

Post-Marketing Pharmacovigilance of Canakinumab from the FDA Adverse Event Reporting System (FAERS) [PDF]

Pharmaceuticals
Background: Canakinumab, a humanized anti-IL-1β monoclonal antibody, is known for its ability to suppress IL-1β-mediated inflammation. However, continuous monitoring of its safety remains essential.
Weidong Zhang, Yunzhou Chen, Zeyu Yao, Mengling Ouyang, Minghui Sun, Shupeng Zou   +5 more
doaj   +2 more sources

Safety assessment of ripretinib: a real-world adverse event analysis from the food and drug administration adverse event reporting system [PDF]

Frontiers in Oncology
BackgroundRipretinib has been approved for the treatment of gastrointestinal stromal tumors (GIST). As a novel therapy, several adverse reactions remain unidentified, necessitating a thorough safety evaluation.
Sentai Wang, Hewen Chen, Yuying Zhou, Jianfeng Chen, Jiwei Cao   +4 more
doaj   +2 more sources

Disproportionality analysis of reslizumab based on the FDA Adverse Event Reporting System [PDF]

Therapeutic Advances in Drug Safety
Background: With the increasing prescription of reslizumab for severe asthma with an eosinophilic phenotype, a real-world pharmacovigilance analysis of reslizumab is urgently required to detect potential unreported adverse events (AEs) in clinical ...
Huqun Li, Cuilian Guo, Chongshu Wang
doaj   +2 more sources